Trial Profile
A Phase 1b Open-label Study of Betalutin in Combination With Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma (Archer-1)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Lutetium-177 lilotomab satetraxetan (Primary) ; Lutetium-177 lilotomab satetraxetan (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions
- Acronyms ARCHER-1; LYMRIT-37-07
- Sponsors Nordic Nanovector
- 30 Sep 2022 Status changed from active, no longer recruiting to completed.
- 23 Sep 2022 This trial has been completed in Norway (Date of the global end of the trial : 08-Aug-2022), according to European Clinical Trials Database record.
- 11 Feb 2022 Planned End Date changed from 1 Jun 2025 to 1 Dec 2022.